Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.

Powell TJ, Rijal P, McEwen-Smith RM, Byun H, Hardwick M, Schimanski LM, Huang KA, Daniels RS, Townsend ARM.

J Gen Virol. 2019 Mar;100(3):431-445. doi: 10.1099/jgv.0.001228. Epub 2019 Feb 4.

PMID:
30714896
2.

Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans.

Huang KA, Rijal P, Jiang H, Wang B, Schimanski L, Dong T, Liu YM, Chang P, Iqbal M, Wang MC, Chen Z, Song R, Huang CC, Yang JH, Qi J, Lin TY, Li A, Powell TJ, Jan JT, Ma C, Gao GF, Shi Y, Townsend AR.

Nat Microbiol. 2019 Feb;4(2):306-315. doi: 10.1038/s41564-018-0303-7. Epub 2018 Nov 26.

PMID:
30478290
3.

M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.

Cole SL, Dunning J, Kok WL, Benam KH, Benlahrech A, Repapi E, Martinez FO, Drumright L, Powell TJ, Bennett M, Elderfield R, Thomas C; MOSAIC investigators, Dong T, McCauley J, Liew FY, Taylor S, Zambon M, Barclay W, Cerundolo V, Openshaw PJ, McMichael AJ, Ho LP.

JCI Insight. 2017 Apr 6;2(7):e91868. doi: 10.1172/jci.insight.91868.

4.

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease.

Jorquera PA, Oakley KE, Powell TJ, Palath N, Boyd JG, Tripp RA.

Vaccines (Basel). 2015 Oct 12;3(4):829-49. doi: 10.3390/vaccines3040829.

5.

The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.

Wegmann F, Moghaddam AE, Schiffner T, Gartlan KH, Powell TJ, Russell RA, Baart M, Carrow EW, Sattentau QJ.

Clin Vaccine Immunol. 2015 Sep;22(9):1004-12. doi: 10.1128/CVI.00736-14. Epub 2015 Jul 1.

6.

Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination.

Peng Y, Wang B, Talaat K, Karron R, Powell TJ, Zeng H, Dong D, Luke CJ, McMichael A, Subbarao K, Dong T.

Front Immunol. 2015 Jun 2;6:287. doi: 10.3389/fimmu.2015.00287. eCollection 2015.

7.

Focused antibody response to influenza linked to antigenic drift.

Huang KY, Rijal P, Schimanski L, Powell TJ, Lin TY, McCauley JW, Daniels RS, Townsend AR.

J Clin Invest. 2015 Jul 1;125(7):2631-45. doi: 10.1172/JCI81104. Epub 2015 May 26.

8.

Autophagy is a critical regulator of memory CD8(+) T cell formation.

Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, Panse I, Watson AS, Cerundolo V, Townsend AR, Klenerman P, Simon AK.

Elife. 2014 Nov 11;3. doi: 10.7554/eLife.03706.

9.

Public health research: Institutional review board review or no institutional review board review?

Koller KR, Powell TJ, Wolfe AW.

J Pediatr. 2014 Aug;165(2):420. doi: 10.1016/j.jpeds.2014.04.040. Epub 2014 Jun 2. No abstract available.

PMID:
24882498
10.

Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Jorquera PA, Choi Y, Oakley KE, Powell TJ, Boyd JG, Palath N, Haynes LM, Anderson LJ, Tripp RA.

PLoS One. 2013 Sep 10;8(9):e74905. doi: 10.1371/journal.pone.0074905. eCollection 2013.

11.

Patient factors associated with failure to diagnose tuberculosis in the emergency department.

Geyer BC, Godwin P, Powell TJ, Moffitt MP, LoVecchio F.

J Emerg Med. 2013 Nov;45(5):658-65. doi: 10.1016/j.jemermed.2013.05.002. Epub 2013 Aug 7.

PMID:
23932702
12.

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.

Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T.

PLoS One. 2013 May 3;8(5):e62778. doi: 10.1371/journal.pone.0062778. Print 2013.

13.

Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Powell TJ, Tang J, Derome ME, Mitchell RA, Jacobs A, Deng Y, Palath N, Cardenas E, Boyd JG, Nardin E.

Vaccine. 2013 Apr 8;31(15):1898-904. doi: 10.1016/j.vaccine.2013.02.027. Epub 2013 Feb 26.

14.

High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection.

Zhao Y, Zhang YH, Denney L, Young D, Powell TJ, Peng YC, Li N, Yan HP, Wang DY, Shu YL, Kendrick Y, McMichael AJ, Ho LP, Dong T.

Am J Respir Crit Care Med. 2012 Dec 15;186(12):1292-7. doi: 10.1164/rccm.201207-1245OC. Epub 2012 Oct 18.

PMID:
23087026
15.

Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.

Powell TJ, Silk JD, Sharps J, Fodor E, Townsend AR.

J Virol. 2012 Dec;86(24):13397-406. doi: 10.1128/JVI.01820-12. Epub 2012 Sep 26.

16.

Redox regulation of cysteine-dependent enzymes in neurodegeneration.

Guttmann RP, Powell TJ.

Int J Cell Biol. 2012;2012:703164. doi: 10.1155/2012/703164. Epub 2012 Jul 5.

17.

A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF).

Bai F, Asojo OA, Cirillo P, Ciustea M, Ledizet M, Aristoff PA, Leng L, Koski RA, Powell TJ, Bucala R, Anthony KG.

J Biol Chem. 2012 Aug 31;287(36):30653-63. doi: 10.1074/jbc.M112.385583. Epub 2012 Jul 10.

18.

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.

Clin Infect Dis. 2012 Jul;55(1):19-25. doi: 10.1093/cid/cis327. Epub 2012 Mar 22. Erratum in: Clin Infect Dis. 2019 Jun 18;69(1):195.

19.

Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections.

Powell TJ, Fox A, Peng Y, Quynh Mai le T, Lien VT, Hang NL, Wang L, Lee LY, Simmons CP, McMichael AJ, Farrar JJ, Askonas BA, Duong TN, Thai PQ, Thu Yen NT, Rowland-Jones SL, Hien NT, Horby P, Dong T.

J Infect Dis. 2012 Jan 1;205(1):20-7. doi: 10.1093/infdis/jir689. Epub 2011 Nov 11.

20.

Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo.

Powell TJ, Palath N, DeRome ME, Tang J, Jacobs A, Boyd JG.

Vaccine. 2011 Jan 10;29(3):558-69. doi: 10.1016/j.vaccine.2010.10.001. Epub 2010 Oct 15.

PMID:
20951665
21.

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L.

PLoS One. 2008 May 21;3(5):e2257. doi: 10.1371/journal.pone.0002257.

22.

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ.

Vaccine. 2008 Jan 10;26(2):201-14. Epub 2007 Nov 20.

PMID:
18063235
23.

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ.

J Infect Dis. 2007 Jun 1;195(11):1607-17. Epub 2007 Apr 17.

PMID:
17471430
24.

Different evolutionary histories of the two classical class I genes BF1 and BF2 illustrate drift and selection within the stable MHC haplotypes of chickens.

Shaw I, Powell TJ, Marston DA, Baker K, van Hateren A, Riegert P, Wiles MV, Milne S, Beck S, Kaufman J.

J Immunol. 2007 May 1;178(9):5744-52.

25.

Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus.

Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW.

J Immunol. 2007 Jan 15;178(2):1030-8.

26.

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ.

Vaccine. 2007 Jan 8;25(4):763-75. Epub 2006 Aug 22.

PMID:
16968658
27.

Peptide motifs of the single dominantly expressed class I molecule explain the striking MHC-determined response to Rous sarcoma virus in chickens.

Wallny HJ, Avila D, Hunt LG, Powell TJ, Riegert P, Salomonsen J, Skjødt K, Vainio O, Vilbois F, Wiles MV, Kaufman J.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1434-9. Epub 2006 Jan 23.

28.

The immune system provides a strong response to even a low exposure to virus.

Powell TJ, Dwyer DW, Morgan T, Hollenbaugh JA, Dutton RW.

Clin Immunol. 2006 Apr;119(1):87-94. Epub 2006 Jan 4.

PMID:
16386960
29.

Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue.

Grand CL, Powell TJ, Nagle RB, Bearss DJ, Tye D, Gleason-Guzman M, Hurley LH.

Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):516. No abstract available.

30.

CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency.

Powell TJ, Brown DM, Hollenbaugh JA, Charbonneau T, Kemp RA, Swain SL, Dutton RW.

Clin Immunol. 2004 Oct;113(1):89-100.

PMID:
15380534
31.

Cutting edge: regulation of CD8+ T cell effector population size.

Kemp RA, Powell TJ, Dwyer DW, Dutton RW.

J Immunol. 2004 Sep 1;173(5):2923-7.

32.

The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4.

Seenisamy J, Rezler EM, Powell TJ, Tye D, Gokhale V, Joshi CS, Siddiqui-Jain A, Hurley LH.

J Am Chem Soc. 2004 Jul 21;126(28):8702-9.

PMID:
15250722
33.
34.
35.

Predictors of psychosocial outcomes for patients with mood disorders: the effects of self-help group participation.

Powell TJ, Yeaton W, Hill EM, Silk KR.

Psychiatr Rehabil J. 2001 Summer;25(1):3-11.

PMID:
11529450
36.
37.

Psychiatrists' referrals to self-help groups for people with mood disorders.

Powell TJ, Silk KR, Albeck JH.

Psychiatr Serv. 2000 Jun;51(6):809-11.

PMID:
10828116
38.

A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes.

Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, MacPherson GG.

J Exp Med. 2000 Feb 7;191(3):435-44.

39.

Derivation of temporary emergency exposure limits (TEELs).

Craig DK, Davis JS, Hansen DJ, Petrocchi AJ, Powell TJ, Tuccinardi TE Jr.

J Appl Toxicol. 2000 Jan-Feb;20(1):11-20.

PMID:
10641012
40.

Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.

Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L, Levitzki A.

Br J Dermatol. 1999 Nov;141(5):802-10.

PMID:
10583160
41.

Recommended default methodology for analysis of airborne exposures to mixtures of chemicals in emergencies.

Craig DK, Baskett RL, Davis JS, Dukes L, Hansen DJ, Petrocchi AJ, Powell TJ, Sutherland PJ, Tuccinardi TE Jr.

Appl Occup Environ Hyg. 1999 Sep;14(9):609-17. Review.

PMID:
10510523
42.

Attitudes of AA contact persons toward group participation by persons with a mental illness.

Meissen G, Powell TJ, Wituk SA, Girrens K, Arteaga S.

Psychiatr Serv. 1999 Aug;50(8):1079-81.

PMID:
10445659
43.

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G.

Cancer Res. 1999 Jan 1;59(1):99-106.

44.

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.

Clin Cancer Res. 1997 Jul;3(7):1167-77.

45.

Activation of T Cells by Autoantigen Immobilized by Specific Antibodies

Powell TJ, Quan J, Freund E, van Schooten WCA.

Methods. 1996 Jun;9(3):453-7.

PMID:
8812700
46.

A follow-up study of patients hospitalized after minor head injury.

Powell TJ, Collin C, Sutton K.

Disabil Rehabil. 1996 May;18(5):231-7.

PMID:
8743300
47.

A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK.

J Immunother Emphasis Tumor Immunol. 1995 May;17(4):209-21.

PMID:
7582257
48.

Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies.

Baskin JG, Powell TJ Jr, Srinivas RV, Elliott M, Lamon EW.

Immunol Res. 1995;14(4):292-316. Review.

PMID:
8722045
49.

The secreted tumor-associated antigen 90K is a potent immune stimulator.

Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al.

J Biol Chem. 1994 Jul 15;269(28):18401-7.

50.

Ontogeny of tolerogen-responsive lymphocytes following neonatal inoculation of class II disparate semiallogeneic cells.

Socarras S, Matriano J, Powell TJ, Streilein JW.

Transpl Immunol. 1993;1(2):114-25.

PMID:
8081769

Supplemental Content

Loading ...
Support Center